Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Drug Naive Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1136 participants.
Also called NCT02273050
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,136 participants
- Sponsor
- Registry
-
NCT02273050
-
- Other papers using this trial's data
- Efficacy and safety of saxagliptin in combination with metformin as initial therapy in Chinese patients with type 2 diabetes: Results from the START study, a multicentre, randomized, double-blind, active-controlled, phase 3 trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT02273050. Randomized; quadruple masking; primary purpose treatment. Start 2014-12 (registry gives no type); primary completion 2016-08 (actual). Results posted on 2018-02-05.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Drug Naive Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Saxagliptin 5 mg
- Intervention (Drug)
- Placebo 5 mg for Saxagliptin
- Intervention (Drug)
- Placebo 500 mg for metformin (with titration)
- Intervention (Drug)
- Metformin 500 mg with titration
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct02273050- Content hash
087882a971bccfde4b9406d7bdb66448dd74c6ed7e0d52f150d62e5bd7b64931